TerminatedPhase 2

Ataluren for Nonsense Mutation Methylmalonic Acidemia

Stopped: Terminated due to low enrollment and unclear pharmacologic effect in available pharmacodynamic data (not due to any safety concerns).

Belgium, France, Germany11 participantsStarted 2010-07-19

Plain-language summary

Methylmalonic acidemia (MMA) is a rare genetic disorder caused by mutations in the gene for mitochondrial enzyme methylmalonyl-CoA mutase (MCM) or in one of the genes for adenosylcobalamin (AdoCbl). Lack of these proteins causes toxic elevations of methylmalonic acid (MMacid) in blood, urine, and other tissues. A specific type of mutation, called a nonsense (premature stop codon) mutation, is the cause of the disease in approximately 5% to 20% of participants with mutations in the MCM gene, and approximately 20% to \>50% of participants with mutations in one of the AdoCbl genes. Ataluren is an orally delivered, investigational drug that acts to overcome the effects of the premature stop codon, potentially enabling the production of functional MCM/AdoCbl. This study is a Phase 2a trial evaluating the safety and activity of ataluren in participants with MMA due to a nonsense mutation. The main purpose of this study is to understand whether ataluren can safely decrease MMacid levels.

Who can participate

Age range2 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Major Inclusion Criteria: * Ability to provide written informed consent (parental/guardian consent if applicable)/assent (if applicable) * Age ≥2 years * Phenotypic evidence of methylmalonic acidemia (MMA) based on the presence of characteristic clinical symptoms or signs and an elevated plasma MMacid level (\>0.27 micromole/liter (umol/L) * Presence of a nonsense mutation in at least 1 allele of the mutase (mut), Cobalamin A (cblA), or Cobalamin B (cblB) gene * Glomerular filtration rate ≥30 milliliters (mL)/minutes/1.73 meters squared (m\^2), serum aminotransferase values ≤2.5\*the upper limit of normal, serum bilirubin ≤1.5\*the upper limit of normal, plasma adrenocorticotropic (ACTH) within normal limits * Willingness and ability to comply with scheduled visits, drug administration plan, study restrictions, and study procedures Major Exclusion Criteria: * Known hypersensitivity to any of the ingredients or excipients of the study drug * Any change in chronic treatment for MMA within 2 months prior to start of screening laboratory assessments * Episode of metabolic decompensation within 1 month prior to start of Screening laboratory assessments * History of organ transplantation * Ongoing dialysis for renal dysfunction

What they're measuring

Plasma Methylmalonic Acid (MMacid) Levels

Timeframe: Baseline and Day 28 and Day 29 (last day of dosing) of Cycles 1 and 2

Trial details

NCT IDNCT01141075

SponsorPTC Therapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2011-11-03

Results submitted2020-05-28